BIOLIDICS LTD.

Company Overview

Biolidics, founded in 2009 as a spin-off from the National University of Singapore and Singapore-MIT Alliance for Research and Technology, is developing cell enrichment systems, combining these with other analytical tests, and applying to a wide range of applications for cancer diagnosis, prognosis, treatment selection and monitoring.

The company has developed a fully automated in vitro diagnostic (IVD) medical device (ClearCell FX1 System) and the CTChip FR1 biochip. These platforms are used to perform liquid biopsy tests for the presence of CTCs.

The company’s business model is to sell ClearCell FX1 Systems, sell the accompanying CTChip FRI biochips and other consumables (each chip can be used once for a liquid biopsy test), and develop a range of LDTs that will, in turn, drive usage of the ClearCell FX1 System.

Biolidic’s approach uses a label-free method to enrich CTCs and preserves them in their original state so they are viable for use in diagnostic tests.

The ClearCell FX1 system, which has a Class 1 registration from the China National Medical Products Administration, is being used in LDT’s collaborations by several institutions in China, including the Agen Medicine Laboratory Technology Company, TopGene Medical Laboratory Company, Genecast Biotechnology, and the Holistic Integrative Pharmacy Institute at Hangzhou Normal University.

In September 2019, Biolidics began collaborating with China’s Hangzhou Normal University in the field of cancer biomarkers. The goal of this alliance was to validate CTCs harvested using Biolidic’s technology, as lung cancer biomarkers.

In November 2019, Biolidics formed a partnership with Sysmex Corp. The partners agreed to jointly develop assays in the field of CTCs using respective technologies (ClearCell FX1 and molecular imaging flow cytometer MI-FCM) and promote assay development, applications and market development for further commercialization of assays. After clinical validation by SAM Laboratories (an affiliate of Biolidics), Biolidics will commercialize the test in Asian markets outside Japan.

In December 2019, Biolidics formed a distribution partnership with IncelDx. As part of the agreement, Biolidics began including IncelDx’s bioINK PD-L1 CTC core kit into its ClearCell FX1 system.